^
    Back
    Association details:
    Biomarker:FGFR2-KIAA1217 fusion
    Cancer:Cholangiocarcinoma
    Drug:derazantinib (ARQ 087) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASCO 2015
    Title:

    Phase 1, First-in-Human Study of ARQ 087, an Oral pan- Fibroblast Growth Factor Receptor (FGFR) Inhibitor, in Patients with Advanced Solid Tumors

    Excerpt:
    "ARQ 087 showed a manageable safety profile in subjects with advanced solid tumors...Patient 053-0060 with iCCA (FGFR2 KIAA1217 fusion) whose disease progressed after 4 regimens of systemic therapy has a minor durable response: C6D1 – 26% decrease..."
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ESMO-GI 2016
    Title:

    ARQ 087, an Oral Pan- Fibroblast Growth Factor Receptor (FGFR) Inhibitor, in Patients with Advanced and/or Metastatic Intrahepatic Cholangiocarcinoma (iCCA)

    Excerpt:
    This is an open-label multi-center Phase 1/2 dose-escalation (Part 1) and signal-finding (Part 2) study of ARQ 087....Patient 0060 with iCCA (FGFR2-KIAA1217 fusion) whose disease progressed after four prior regimens of systemic therapy had a partial response: 32% decrease in tumor burden, completed 10 cycles.
    DOI:
    10.3252/pso.eu.18wgic.2016